Arbutus Biopharma Corp Debt Securities, Available-for-sale, Amortized Cost
Arbutus Biopharma Corp (ABUS) had Debt Securities, Available-for-sale, Amortized Cost of $73.51 million as of 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Notes › Debt Securities, Available-for-Sale, Amortized Cost
us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis · last filed 2026-08-12
- 2026-06-30: Debt Securities, Available-for-sale, Amortized Cost $73.51M.
- 2026-03-31: Debt Securities, Available-for-sale, Amortized Cost $71.53M.
- 2025-12-31: Debt Securities, Available-for-sale, Amortized Cost $73.38M.
- 2025-09-30: Debt Securities, Available-for-sale, Amortized Cost $71.24M.
| Period end | Debt Securities, Available-for-sale, Amortized Cost | Debt Securities, Available-for-sale, Amortized Cost as first filed |
|---|---|---|
| 2026-06-30 | $73.51M 10-Q · filed 2026-08-12 | |
| 2026-03-31 | $71.53M 10-Q · filed 2026-05-13 | |
| 2025-12-31 | $73.38M 10-Q · filed 2026-08-12 | |
| 2025-09-30 | $71.24M 10-Q · filed 2025-11-13 | |
| 2025-06-30 | $60.68M 10-Q · filed 2025-08-06 | |
| 2025-03-31 | $75.61M 10-Q · filed 2025-05-14 | |
| 2024-12-31 | $86.24M 10-Q · filed 2025-11-13 | |
| 2021-12-31 | $35.77M 10-Q · filed 2022-11-09 | $81.87M 10-K · filed 2022-03-03 |
| 2021-03-31 | $52.52M 10-Q · filed 2021-05-05 | |
| 2020-12-31 | $71.00M 10-K · filed 2022-03-03 | |
| 2019-12-31 | $59.03M 10-K · filed 2021-03-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 |